Activity Overview
More than 50 million people suffer from chronic pain in this country. Often this pain has no cure. It may be nociceptive, neuropathic, or disease specific. Left untreated, chronic pain may affect sleep, quality of life, mental health, and productivity. The condition is difficult to diagnose and manage because an individual’s perception of their pain is subjective, and the cause varies between patients. Pharmacists are readily available to patients and fellow colleagues for questions regarding pain management. They can optimize treatment strategies for improved patient outcomes, as well as provide physicians and staff with important information regarding administration, side effects, drug interaction potential, and efficacy of pharmacological agents used to address chronic pain. In order to provide this type of care, pharmacists need an in-depth understanding of all of the available drug options for pain management.

Agenda

9:00 – 9:15 AM Registration
9:15 – 9:30 AM Introduction and Pre-Symposium Outcomes Survey
Bruce R. Canaday, PharmD, FASHP, FAPhA
9:30 – 10:10 AM      Current State of Chronic Pain Management
John P. Barbuto, MD, PC
10:10 – 10:50 AM New and Emerging Therapies in Chronic Pain
Lynn Webster, MD, FACPM, FASAM
10:50 – 11:30 AM Perspectives for the Managed Care Pharmacist
Bruce R. Canaday, PharmD, FASHP, FAPhA
11:30 – 11:45 AM Faculty Debate, Post-Symposium Outcomes Survey, and Question & Answer Session
Bruce R. Canaday, PharmD, FASHP, FAPhA
11:45 – 12:30 PM Closing Remarks/Lunch

Goal
The purpose of the symposium is to present evidence-based medicine to managed care pharmacists who are involved in evaluating chronic pain therapies in their institution or practice.

Intended Audience
This activity is designed for managed care pharmacists in attendance at the Academy of Managed Care Pharmacy’s 21st Annual Meeting and Showcase. No prerequisites required.

Learning Objectives
Upon the conclusion of this activity, the participant should be able to:

  • Compare and contrast pharmacologic treatment options for chronic pain.
  • Identify barriers associated with opioid therapy and methods to overcome these obstacles to optimize treatment.
  • Differentiate between new and emerging treatment options relating to abuse-resistant technologies.
  • Manage symptom control and improve quality of life in patients with refractory pain.
  • Implement newly acquired knowledge and skills to optimize patient care (eg, equianalgesic conversion).

The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity.

Accreditation Statement
The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education to provide continuing education for pharmacists.

Credit Designation Statement
The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this application-based educational activity will provide 2.5 contact hours credit (0.25 CEUs). A statement of CE credit will be mailed within 4 weeks following successful completion of the educational activity. Successful completion includes attending the session, signing the attendance sheet, and completion of the educational activity evaluation form. ACPE Program #064-000-09-201-L01-P.

Faculty
Bruce R. Canaday, PharmD, FASHP, FAPhA
Clinical Professor and Vice-Chair
Division of Pharmacy Practice and Experiential Education
University North Carolina Eshelman School of Pharmacy
Chapel Hill, NC
Director, Department of Pharmacotherapy
South East Area Health Education Center
Wilmington, NC

Lynn Webster, MD, FACPM, FASAM
Medical Director
Lifetree Clinical Research and Pain Clinic
President, Utah Academy of Pain Medicine
Salt Lake City, UT

John P. Barbuto, MD, PC
Medical Director
Neurology-in-Focus
HealthSouth Rehabilitation Hospital
Journal of Managed Care Pharmacy Editorial Advisory Board Member
Sandy, UT

Policy on Faculty and Provider Disclosure
It is the policy of The University of Tennessee College of Pharmacy that the faculty and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during the presentation(s). Detailed disclosures will be made in the course handout materials.

Americans with Disabilities Act (ADA)
The University of Tennessee College of Pharmacy fully complies with the legal requirements of the ADA and the rules and regulations thereof. Please notify us if you have any special needs.

Grievance Policy
A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of an educational activity sponsored or cosponsored by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.

Fee Information
There is no fee for this educational activity.

This activity is made possible by an educational grant from King Pharmaceuticals, Inc.
 
     
Home | Contact Us | View Account | Need Help? | Subscription